Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo

被引:28
作者
Baumann, D. [1 ]
Bachert, C. [2 ]
Hoegger, P. [1 ]
机构
[1] Univ Wurzburg, Inst Pharm & Lebensmittelchem, D-97074 Wurzburg, Germany
[2] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airway Res Lab, B-9000 Ghent, Belgium
关键词
glucocorticoids; human nasal tissue; pharmacodynamics; pharmacokinetics; rhinitis; SEASONAL ALLERGIC RHINITIS; HUMAN RECEPTOR KINETICS; AIRWAY SURFACE LIQUID; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE; CYSTIC-FIBROSIS; IN-VITRO; SPRAY; BUDESONIDE; CYTOKINES;
D O I
10.1111/j.1365-2222.2009.03306.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
P>Background Intranasal glucocorticoids represent the most effective pharmacologic treatment of allergic rhinitis. So far, no clinical data are available that compare fluticasone furoate (FF) with other intranasally applied glucocorticoids. Objective Because the pharmacokinetic behaviour of drugs governs their presence at the therapeutic target site we analysed selected in vitro properties of FF in comparison with triamcinolone acetonide (TCA), budesonide (Bud), fluticasone propionate (FP) and mometasone furoate (MF). Additionally, we determined the anti-inflammatory activity of the glucocorticoid fraction residing in human nasal tissue samples after washing. Methods We analysed the solubility of the compounds in artificial human nasal fluid and the retention in human nasal tissue as well as typical spray volumes of commercially available drug preparations. As an anti-inflammatory measure, we evaluated the inhibition of IL-8 release from epithelial cells. Results FF is delivered in the smallest application volume per spray. Despite the low aqueous solubility of glucocorticoids, a fraction of the compounds is already dissolved in the aqueous supernatants of drug preparations (Bud > TCA > FP > MF > FF). The dissolution of FP, MF and FF was significantly enhanced in artificial nasal fluid and FF displayed the most pronounced enhancement of solubility in the presence of proteins. Consistent with this result, the highest retention in nasal tissue was observed for FF, followed by FP > MF > Bud > TCA. After washing of the nasal tissue samples, all compounds inhibited IL-8 release, with FF displaying the highest activity. Conclusion FF displayed beneficial properties for nasal application. Its low application volume per spray is a prerequisite for effective drug utilization by avoiding immediate loss by nose runoff or drip down the throat. Sustained dissolution and high tissue binding of FF should contribute towards an extended presence of compounds in nasal tissue as a basis for a prolonged pharmacologic activity.
引用
收藏
页码:1540 / 1550
页数:11
相关论文
共 46 条
  • [1] Absolute bioavailability of intranasal fluticasone furoate in healthy subjects
    Allen, Ann
    Down, Geoff
    Newland, Amy
    Reynard, Karen
    Rousell, Vicki
    Salmon, Emma
    Scott, Rebecca
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (07) : 1415 - 1420
  • [2] Intranasal Mometasone Furoate Alleviates the Ocular Symptoms Associated with Seasonal Allergic Rhinitis: Results of a Post Hoc Analysis
    Anolik, Robert
    Nathan, Robert A.
    Schenkel, Eric
    Danzig, Melvyn R.
    Gates, Davis
    Varghese, Santosh
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2008, 147 (04) : 323 - 330
  • [3] NASAL MUCOSAL INFLAMMATION HAS NO EFFECT ON THE ABSORPTION OF INTRANASAL TRIAMCINOLONE ACETONIDE
    ARGENTI, D
    COLLIGON, I
    HEALD, D
    ZIEMNIAK, J
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (08) : 854 - 858
  • [4] Permeability issues in nasal drug delivery
    Arora, P
    Sharma, S
    Garg, S
    [J]. DRUG DISCOVERY TODAY, 2002, 7 (18) : 967 - 975
  • [5] PROINFLAMMATORY CYTOKINES - MEASUREMENT IN NASAL SECRETION AND INDUCTION OF ADHESION RECEPTOR EXPRESSION
    BACHERT, C
    WAGENMANN, M
    HAUSER, U
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1995, 107 (1-3) : 106 - 108
  • [6] SOLUBILITY AND DISSOLUTION OF TRIAMCINOLONE ACETONIDE
    BLOCK, LH
    PATEL, RN
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1973, 62 (04) : 617 - 621
  • [7] Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application
    Bonsmann, U
    Bachert, C
    Delank, KW
    Rohdewald, P
    [J]. ALLERGY, 2001, 56 (06) : 532 - 535
  • [8] Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen)
    Bousquet, J.
    Khaltaev, N.
    Cruz, A. A.
    Denburg, J.
    Fokkens, W. J.
    Togias, A.
    Zuberbier, T.
    Baena-Cagnani, C. E.
    Canonica, G. W.
    van Weel, C.
    Agache, I.
    Ait-Khaled, N.
    Bachert, C.
    Blaiss, M. S.
    Bonini, S.
    Boulet, L. -P.
    Bousquet, P. -J.
    Camargos, P.
    Carlsen, K. -H.
    Chen, Y.
    Custovic, A.
    Dahl, R.
    Demoly, P.
    Douagui, H.
    Durham, S. R.
    van Wijk, R. Gerth
    Kalayci, O.
    Kaliner, M. A.
    Kim, Y. -Y.
    Kowalski, M. L.
    Kuna, P.
    Le, L. T. T.
    Lemiere, C.
    Li, J.
    Lockey, R. F.
    Mavale-Manuel, S.
    Meltzer, E. O.
    Mohammad, Y.
    Mullol, J.
    Naclerio, R.
    Hehir, R. E. O.
    Ohta, K.
    Ouedraogo, S.
    Palkonen, S.
    Papadopoulos, N.
    Passalacqua, G.
    Pawankar, R.
    Popov, T. A.
    Rabe, K. F.
    Rosado-Pinto, J.
    [J]. ALLERGY, 2008, 63 : 8 - +
  • [9] Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays
    Daley-Yates, PT
    Kunka, RL
    Yin, Y
    Andrews, SM
    Callejas, S
    Ng, C
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (04) : 265 - 268
  • [10] DAVID HA, 1954, BIOMETRIKA, V41, P482, DOI 10.1093/biomet/41.3-4.482